Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13692403 | 0.83 | ALOX5 (0.47) | ALDH1A1ALOX5ADRA1D | |
| SCHEMBL6642441 | 0.83 | ALOX5 (0.47) | ALDH1A1ALOX5ADRA1D | |
| SCHEMBL10642812 | 0.78 | ALDH1A1 (0.38) | ALDH1A1ALOX5ADRA1DLMNAMAPT | |
| SCHEMBL11421425 | 0.77 | GABRA1 (0.40) | ALDH1A1 | |
| SCHEMBL10566217 | 0.77 | ALOX5 (0.46) | ALDH1A1ALOX5ADRA1DRIPK1NPC1 | |
| SCHEMBL23877337 | 0.76 | KEAP1 (0.31) | — | |
| SCHEMBL12702042 | 0.76 | FBP1 (0.32) | — | |
| SCHEMBL9036511 | 0.76 | GABRA1 (0.39) | ALDH1A1ALOX5LMNAMAPTNPC1 | |
| SCHEMBL22863972 | 0.76 | SLC6A3 (0.41) | ALDH1A1LMNAMAPT | |
| SCHEMBL12434723 | 0.76 | ADRA1D (0.40) | ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | claimed |
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| WO-2025044926-A1 | THIENYLSULFONYL CARBAMATES AS AT2R AGONISTS | 武汉人福创新药物研发中心有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119504723-A | Thiophene sulfonyl carbamates as AT2R agonists | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-116891464-A | AT2R agonist | 武汉人福创新药物研发中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023193733-A1 | AT2R AGONIST | 武汉人福创新药物研发中心有限公司 | 2023-10-12 | — | — | WO | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20080176815-A1 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2008-07-24 | — | — | US | disclosed |
| WO-2007137962-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | HOFFMANN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
| US-7291623-B2 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2007-11-06 | — | — | US | disclosed |
| US-20060161008-A1 | Chloromethylation of thiophene, using aqueous concentrated hydrochloric acid, gaseous hydrogen chloride and paraformaldehyde, in the presence of acetone or methyl-ethyl-ketone or methyl-isobutyl-ketone to produce 2-chloro-methyl-thiophene | SANOFI (FR) | 2006-07-20 | — | — | US | disclosed |
| CN-1260224-C | Chloromethylation of thiophene | SANOF SYNTHELABO (FR) | 2006-06-21 | — | — | CN | disclosed |
| EP-1392672-B1 | CHLOROMETHYLATION OF THIOPHENE | SANOFI AVENTIS (FR) | 2005-05-04 | — | — | EP | disclosed |
| CN-1511148-A | Chloromethylation of thiophenes | ��ŵ�Ѻϳ�ʵ���� | 2004-07-07 | — | — | CN | disclosed |
| EP-1392672-A1 | CHLOROMETHYLATION OF THIOPHENE | Sanofi-Aventis (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002094806-A1 | CHLOROMETHYLATION OF THIOPHENE | SANOFI-SYNTHELABO (FR) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | ALDH1A1 1680/4885ALOX5 3687/4885ADRA1D 4770/4885 |
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | ALDH1A1 2365/4885ALOX5 2253/4885ADRA1D 13/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | ALDH1A1 4642/4885ALOX5 4711/4885ADRA1D 4243/4885 |
| US-20080176815-A1 | Compounds that interact with kinases | MAP3K6, MAP3K20, MAP4K2 | ALDH1A1 3275/4885ALOX5 4292/4885ADRA1D 3618/4885 |
| US-20070281979-A1 | Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents | FBP1, PFKFB1, PFKFB3 | ALDH1A1 565/4885ALOX5 3688/4885ADRA1D 2205/4885 |
| US-20060161008-A1 | Chloromethylation of thiophene, using aqueous concentrated hydrochloric acid, gaseous hydrogen chloride and paraformaldehyde, in the presence of acetone or methyl-ethyl-ketone or methyl-isobutyl-ketone to produce 2-chloro-methyl-thiophene | TPMT, MCCC2, MGMT | ALDH1A1 522/4885ALOX5 1894/4885ADRA1D 3003/4885 |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | TLR9, TLR7, TLR8 | ALDH1A1 3767/4885ALOX5 2221/4885ADRA1D 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.